Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.1 USD | +2.00% | +2.62% | -34.53% |
May. 14 | Transcript : Syros Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | Syros Pharmaceuticals, Inc. Agrees to Amend Its Loan Agreement with Oxford Finance LLC | CI |
Business Summary
Number of employees: 68
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Gene Control Medicines
100.0
%
| 15 | 100.0 % | 10 | 100.0 % | -33.23% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 15 | 100.0 % | 10 | 100.0 % | -33.23% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Conley Chee
CEO | Chief Executive Officer | 54 | 21-09-26 |
Nancy Simonian
CEO | Chief Executive Officer | 63 | 12-10-31 |
Jason Haas
DFI | Director of Finance/CFO | 56 | 21-10-11 |
David Roth
CTO | Chief Tech/Sci/R&D Officer | 61 | 15-12-06 |
Gerald Quirk
ADM | Chief Administrative Officer | 56 | 16-08-31 |
Karen Hunady
IRC | Investor Relations Contact | - | 22-09-30 |
Lisa Roberts
HRO | Human Resources Officer | - | 11-12-31 |
Kristin Stephens
PRN | Corporate Officer/Principal | 51 | 15-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 56 | 17-06-11 | |
Tim Tyson
BRD | Director/Board Member | 71 | 22-09-15 |
Marsha Fanucci
BRD | Director/Board Member | 70 | 15-10-18 |
Deborah Dunsire
BRD | Director/Board Member | 61 | 21-09-08 |
Peter Wirth
CHM | Chairman | 73 | 17-01-29 |
Nancy Simonian
CEO | Chief Executive Officer | 63 | 12-10-31 |
Richard Young
FOU | Founder | 70 | 11-11-08 |
S. Gail Eckhardt
BRD | Director/Board Member | 66 | 20-09-07 |
Andrew Oh
BRD | Director/Board Member | 53 | 22-09-15 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 26,728,337 | 26,310,119 ( 98.44 %) | 0 | 98.44 % |
Company contact information
Syros Pharmaceuticals, Inc.
35 CambridgePark Drive 4th floor
02140-2325, Cambridge
+617 744 1340
http://www.syros.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.53% | 136M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- SYRS Stock
- Company Syros Pharmaceuticals, Inc.